英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
geschwa查看　geschwa　在百度字典中的解释百度英翻中〔查看〕
geschwa查看　geschwa　在Google字典中的解释Google英翻中〔查看〕
geschwa查看　geschwa　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Investors | Eli Lilly and Company
    The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts
  • Lilly reports fourth-quarter 2025 financial results and provides 2026 . . .
    The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts
  • Presentation - Eli Lilly and Company
    JUNE 2, 2024 This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors The company's results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; litigation
  • Webcasts Presentations | Eli Lilly and Company
    The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts
  • Lilly announces plans to build $5 billion manufacturing facility in . . .
    INDIANAPOLIS, Sept 16, 2025 PRNewswire -- Eli Lilly and Company (NYSE: LLY) today announced that it plans to build a $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County The new site will be the company's first dedicated, fully integrated active pharmaceutical ingredient (API) and drug product facility for Lilly's emerging bioconjugate platform and
  • Lilly to acquire Scorpion Therapeutics mutant-selective PI3Kα . . .
    The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts
  • Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an . . .
    INDIANAPOLIS, Nov 1, 2024 PRNewswire -- Eli Lilly and Company (NYSE: LLY) today announced that data from the Phase 3 trial (EMBER-3) for imlunestrant, an oral selective estrogen receptor degrader (SERD), will be reported for the first time in a late-breaking oral presentation at the San Antonio Breast Cancer Symposium (SABCS) taking place December 10-13 in San Antonio, TX EMBER-3 is a
  • Lillys Social Impact Venture Capital Portfolio . . . - Eli Lilly and Company
    The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts
  • Lilly to acquire Ventyx Biosciences to advance oral therapies targeting . . .
    The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts
  • Presentation - investor. lilly. com
    For additional information about the factors that affect the company's business, please see the company's latest Form 10-K and subsequent Forms 10-Q and 8-K filed with the Securities and Exchange Commission Certain financial information in this presentation is presented on a non-GAAP basis Investors should refer to the reconciliations included in this presentation and should consider the





中文字典-英文字典  2005-2009